230 related articles for article (PubMed ID: 12844478)
1. Impact of dihydropyrimidine dehydrogenase on 5-fluorouracil treatment in cancer patients.
Schneider HB; Becker H
Eur J Med Res; 2003 May; 8(5):226-8. PubMed ID: 12844478
[TBL] [Abstract][Full Text] [Related]
2. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
van Kuilenburg AB
Eur J Cancer; 2004 May; 40(7):939-50. PubMed ID: 15093568
[TBL] [Abstract][Full Text] [Related]
3. Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
Lee A; Ezzeldin H; Fourie J; Diasio R
Clin Adv Hematol Oncol; 2004 Aug; 2(8):527-32. PubMed ID: 16163233
[TBL] [Abstract][Full Text] [Related]
4. DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity.
Yang CG; Ciccolini J; Blesius A; Dahan L; Bagarry-Liegey D; Brunet C; Varoquaux A; Frances N; Marouani H; Giovanni A; Ferri-Dessens RM; Chefrour M; Favre R; Duffaud F; Seitz JF; Zanaret M; Lacarelle B; Mercier C
Cancer Chemother Pharmacol; 2011 Jan; 67(1):49-56. PubMed ID: 20204365
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
6. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy.
Ciccolini J; Mercier C; Evrard A; Dahan L; Boyer JC; Duffaud F; Richard K; Blanquicett C; Milano G; Blesius A; Durand A; Seitz JF; Favre R; Lacarelle B
Ther Drug Monit; 2006 Oct; 28(5):678-85. PubMed ID: 17038885
[TBL] [Abstract][Full Text] [Related]
7. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
Schwab M; Zanger UM; Marx C; Schaeffeler E; Klein K; Dippon J; Kerb R; Blievernicht J; Fischer J; Hofmann U; Bokemeyer C; Eichelbaum M;
J Clin Oncol; 2008 May; 26(13):2131-8. PubMed ID: 18299612
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacogenetics in oncology: 5-fluorouracil and the dihydropyrimidine dehydrogenase].
Lazar A; Jetter A
Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1501-4. PubMed ID: 18597209
[TBL] [Abstract][Full Text] [Related]
9. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?
Ciccolini J; Gross E; Dahan L; Lacarelle B; Mercier C
Clin Colorectal Cancer; 2010 Oct; 9(4):224-8. PubMed ID: 20920994
[TBL] [Abstract][Full Text] [Related]
10. [Severe capecitabine-associated toxicity in a patient carrying a mutation in the dihydropyrimidine dehydrogenase gen].
González-Haba E
Farm Hosp; 2012; 36(6):554-5. PubMed ID: 23461455
[No Abstract] [Full Text] [Related]
11. Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question.
van Kuilenburg AB
Cancer Invest; 2006 Mar; 24(2):215-7. PubMed ID: 16537192
[TBL] [Abstract][Full Text] [Related]
12. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
13. Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects.
Gross E; Ullrich T; Seck K; Mueller V; de Wit M; von Schilling C; Meindl A; Schmitt M; Kiechle M
Hum Mutat; 2003 Dec; 22(6):498. PubMed ID: 14635116
[TBL] [Abstract][Full Text] [Related]
14. Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls.
Innocenti F; Ratain MJ
Clin Cancer Res; 2002 May; 8(5):1314; author reply 1315-6. PubMed ID: 12006555
[No Abstract] [Full Text] [Related]
15. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
Ogura K
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
[TBL] [Abstract][Full Text] [Related]
16. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.
Ciccolini J; Mercier C; Blachon MF; Favre R; Durand A; Lacarelle B
J Clin Pharm Ther; 2004 Aug; 29(4):307-15. PubMed ID: 15271097
[TBL] [Abstract][Full Text] [Related]
17. [Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].
Hooiveld EA; van Kuilenburg AB; Haanen JB; Westermann AM
Ned Tijdschr Geneeskd; 2004 Mar; 148(13):626-8. PubMed ID: 15083629
[TBL] [Abstract][Full Text] [Related]
18. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil.
Johnson MR; Hageboutros A; Wang K; High L; Smith JB; Diasio RB
Clin Cancer Res; 1999 Aug; 5(8):2006-11. PubMed ID: 10473079
[TBL] [Abstract][Full Text] [Related]
19. [A case of gastric cancer with decreased dihydropyrimidine dehydrogenase activity].
Kobayashi K; Sumi S; Kidouchi K; Mizuno I; Mohri N; Fukui T; Akamo Y; Takeyama H; Manabe T
Gan To Kagaku Ryoho; 1998 Jul; 25(8):1217-9. PubMed ID: 9679586
[TBL] [Abstract][Full Text] [Related]
20. Dehydropyrimidine dehydrogenase deficiency in a cancer patient undergoing 5-fluorouracil chemotherapy.
Schneider HB; Becker H
Anticancer Res; 2004; 24(2C):1091-2. PubMed ID: 15154628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]